The recent downturn in biotech has battered Massachusetts’ world-renowned sector, and the political climate has only made it ...

The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...

The main reason for the downturn in Moderna’s stock is a significant drop in the demand for its COVID-19 vaccine.

The Food and Drug Administration (FDA) has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike ®.

By Stephanie Brown HealthDay ReporterTUESDAY, June 3, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...

The Food and Drug Administration has approved Moderna's new COVID-19 vaccine, days after the federal government tightened ...

Robert F. Kennedy, Jr., the new Secretary of the U.S. Department of Health and Human Services (HHS), recently announced that ...

Moderna said mNEXSPIKE was approved by the FDA for use in adults aged 65 and up, as well as some individuals aged 12 to 64.

U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said on Tuesday that Moderna has agreed to a true ...

Moderna announced this weekend that the Food and Drug Administration approved its lower-dose Covid-19 vaccine for adults 65 ...

From eligibility to dosage and future rollout, here’s what you need to know about the FDA’s latest vaccine approval.

The Food and Drug Administration approved Moderna's next-generation COVID-19 vaccine for adults 65 and older, the company ...